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Endobronchial tumorAbstract Background: Radiotherapy and chemotherapy are the standard palliative treatments in
patients with inoperable carcinoma of the lung present with obstruction of the central airway but
have limited effectiveness in reopening obstructed airways. Cryosurgery is one of the several tech-
niques that can be used to reopen an obstructed tracheobronchial lumen.
Objective: The aim of this study was to evaluate safety and clinical efficacy of flexible cryoprobe as
an important option to treat the patients with inoperable obstructive central bronchial lung tumors.
Patients and methods: This study was conducted on 38 patients with central endobronchial malig-
nant tumor. A flexible cryoprobe was used during flexible bronchoscopy. The endobronchial tumors
and symptoms were assessed 2 and 6 weeks after cryotherapy.
Results: After 6 weeks, the endobronchial lesions were completely removed in 32/38 patients
(85%), partly removed in 4/38 patients (10%), and could not be removed in 2/38 patients
(5%), with a symptomatic improvement in dyspnea, cough and hemoptysis 78%, 63.0%, 85% after
2 weeks and up to 89%, 84.0%, 100% after 6 weeks respectively.
Conclusion: Cryotherapy using fiberoptic bronchoscopy is a safe with a high efficacy technique in
treating endobronchial malignant obstructive lesions.
 2015 The Egyptian Society of Chest Diseases and Tuberculosis. Production and hosting by Elsevier B.V.
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-
nd/4.0/).Introduction
Lung cancer, the most frequent cause of cancer related death,
is responsible for more than 1 million deaths annually [1,2].
Lung cancer represents >17% of all new cases of cancer
and 28% of all cancer deaths worldwide. At the time ofdiagnosis, >80% of patients are inoperable, resulting in a 5-
year survival rate of 15% [3,4].
Approximately 30% of inoperable patients with carcinoma
of the lung present with obstruction of the central airway,
which can cause distressing symptoms of cough, breathless-
ness, hemoptysis and recurrent infections, and may lead to
gradual asphyxiation [5,6].
Palliative reopening of the affected airways often alleviates
symptoms. Where the possibility of surgery has been
eliminated, radiotherapy and chemotherapy are the standard
palliative treatments but have limited effectiveness in reopening
Table 1 Basic characteristics of study population.
Characteristics N %
M/F 23/15
Age 61.80 ± 8.72
CT tumor size
P3 cm 29 76.32
<3 cm 9 23.68
Lesion localization
Rt. main bronchus 7 18.42
Rt. LL 9 23.68
Rt. UL 2 5.26
Lt. main bronchus 5 13.15
Lt. LL 6 15.78
Lt. UL 9 23.68
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sidered [7].
Interventional bronchoscopy, particularly therapeutic
bronchoscopy, includes many diverse modalities, such as the
Nd:YAG laser, electrocautery, argon plasma coagulation,
photodynamic therapy, airway stenting, brachytherapy, and
cryotherapy, which have advantages and disadvantages [7,8].
The advantage of endobronchial cryotherapy is that it has
been proven effective with minimal complications. It is also
relatively easy to use and economical compared with other
therapeutic modalities. Cryotherapy is safe, with no danger
of bronchial wall perforation, no radiation danger, no risk of
electrical accidents or fires, and does not require much special
training. Disadvantages include delayed results and the
requirement for multiple bronchoscopies to remove debris or
to retreat, which is a serious issue for cryotherapy in a patient
with impending respiratory failure due to an obstructive air-
way lesion [8,9].
The currently available rigid cryoprobe requires rigid
bronchoscopy and general anesthesia, rendering the distal
upper lobe bronchial lesions inaccessible [10].
The development of a thin and flexible cryoprobe has
revolutionized cryotherapy for endobronchial lesions. This
new generation cryoprobe can be passed through a flexible
fiberoptic bronchoscope and cryodestruct nearly all visible air-
way lesions [10,11].
The success of freeze injury, which is the main mechanism
of cryotherapy for malignancy, depends on the cooling rate,
the thawing rate, the lowest temperature achieved, and
repeated freeze–thaw cycles [8,12,13].
Aim of the study
The Current short-term follow-up study aimed to evaluate
safety and clinical efficacy of flexible cryoprobe as an impor-
tant option to treat the patients with inoperable obstructive
central bronchial lung tumors.
Patients and methods
In this study, a total of 38 patients with an endobronchial
malignant lesion were recruited from Chest and Clinical
Oncology departments, Tanta University.
Inclusion criteria: (1) histologically proven carcinoma of
the trachea and bronchi, (2) inoperable carcinoma based on
the position of the tumor, performance status or poor respira-
tory function. Exclusion criteria: (1) severe respiratory distress
and (2) uncorrectable bleeding profile.
Patients were assessed before cryotherapy and 2–6 weeks
after cryotherapy, as regards the: (1) symptomatic; dyspnea,
hemoptysis and cough, (2) chest radiography, (3) respiratory
function tests: forced expiratory volume in one second
(FEV1), and forced vital capacity (FVC) (4) performance sta-
tus, using the Karnofsky scale [14].
The New York Health Association (NYHA) classification
was used for assessment of dyspnea [15]. Hemoptysis was
classified as none, blood tinged, and frank hemoptysis. Cough
was assessed as regards the severity and persistence (does not
disturb sleep or disturbs sleep).
All procedures were carried out during flexible bron-
choscopy that was done in a standard fashion with topicalanesthesia (5% lidocaine) of the oral-nasopharyngeal area
and conscious sedation (IV midazolam).
The distal tip of the bronchoscope was placed about 5 mm
above the lesion and the appropriate cryoprobe was inserted
through the biopsy channel (bronchoscope) into the tumor.
A flexible cryoprobe measuring 90 cm in length and 2.4 mm
in diameter was used (ERBE, Germany). The probe was
cooled with CO2 that decreases the temperature in the probe’s
tip to 70 C within several seconds.
Statistical analysis
A Wilcoxon matched pairs signed rank sum test was carried
out for each outcome variable to determine whether there
was a difference between pre- and post cryotherapy values.
Results were expressed as numeric values (%). A p value of less
than 0.05 was considered significant.
Results
This study was conducted on 38 patients, M/F ratio (23/15),
mean age (61.80) with a central endobronchial malignant
tumor (65% located in Rt. main, Rt. LL, and Lt. UL bronchi),
60% of the tumors at the time of presentation for cryosurgery
at stage IIIb or IV (23 patients), and 40% (15 patients) at stage
II or IIIa Table 1.
The endobronchial lesions, after 2 weeks, were completely
removed in 29/38 patients (76.31%), partly removed in 5/38
patients (13.16%), and could not be removed in 4/38 patients
(10.53%). After 6 Weeks , they were completely removed in
32/38 patients (85%), partly removed in 4/38 patients
(10%), and could not removed in 2/38 patients (5%). So,
there was an objective significant response (p< 0.05) of
malignant endobronchial tumors to cryotherapy (using flexible
cryoprobe) Table 2 and Fig. 1.
As regards the symptomatic improvement, dyspnea was
improved at least one class after 2 weeks in 30/38 patients
(78.94%), with more improvement after 6 weeks in 34/38
patients (89.47%). Cough was improved after 2 weeks in
24/38 patients (63.15%), with more improvement after 6 weeks
in 32/38 patients (84.21%).
Hemoptysis was improved after 2 weeks in 12/14 patients
(85.71%) after 6 weeks in 14/14 patients (100%), completely
controlled Table 3.
Table 3 Symptomatic improvement, 2 weeks and 6 weeks
after cryotherapy.
N %
After 2 weeks
Dyspnea 30/38 78.9
Cough 24/38 63.1
Haemoptysis 12/14 85.7
After 6 weeks
Dyspnea 34/38 89.47
Cough 32/38 84.2
Haemoptysis 14/14 100
Figure 2 Chest X-ray before and after cryotherapy with Rt. lung
collapse resolution.Figure 1 Before and 2 weeks after cryotherapy (completely
removed).
Table 2 Endobronchial lesions response to cryoablation.
Endobronchial lesions: N %
After 2 weeks
Removed 29/38 76.31
Partly removed 5/38 13.16
Not removed 4/38 10.53
After 6 weeks
Removed 32/38 84.2
Partly removed 4/38 10.5
Not removed 2/38 5.2
Table 4 FVC, FEV1, and performance status before and after
cryotherapy.
Before 2 weeks 6 weeks
FVC 1.43 ± 0.57 1.91 ± 0.76 2.41 ± 0.83
FEV1 1.21 ± 0.54 1.82 ± 0.72 2.94 ± 0.98
Perf. St. 54 ± 6 60 ± 7 75 ± 8
Fiberoptic bronchoscopic cryo-ablation 529Resolution of lung collapse in 60% of patients after
2 weeks, with resolution lobe atelectasis in 76% (n= 29) of
patients after 6 weeks Fig 2. Patients (n= 9) with persistent
lung collapse included patients with partly and not removed
tumors (n= 6), with thick secretion (n= 3), and with pro-
gressed extra-luminal compressive tumor (n= 2).
As for functional improvement, there was a significant
improvement in baseline mean FVC from (1.43), to (1.91)
and (2.41) after 2 and 6 weeks. There was a significant
improvement in the baseline mean FEV1 from (1.21), to
(1.82) and (2.94) after 2 and 6 weeks.There was a significant improvement in the baseline mean
Karnofsky score from (54), to (60) and (75) after 2 and 6 weeks
Table 4.
Complications: some minor complications (manageable)
were reported: mild hemoptysis, blood tinged sputum
(7.8%), respiratory distress (5.2%), mild fever (5.2), and
post-operative atrial fibrillation (2.6%). There were no
reported cases of airway perforation, cardiorespiratory arrest
and infection.
Discussion
This study was conducted on 38 patients with intraluminal
inoperable malignant tumors, and complete removal of tumor
was achieved in 76% of cases by the 2nd week, and up to 85%
by the 6th week, only in 2 out of 38 patients tumor could not
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cryosurgery can be divided into immediate and delayed. Imme-
diate mechanisms include the physical effect of intracellular ice
crystal formation, the biochemical effect of cell dehydration
and shrinkage, and thawing effects. The delayed effect involves
vascular stasis and apoptosis [16,17].
This study showed a marked symptomatic improvement in
dyspnea, cough and hemoptysis at 2 weeks and a more marked
improvement at 6 weeks after cryo-ablation.
Also, the study showed an effective improvement in the
lung function measured by FVC and FEV1, and a significant
improvement in the performance status.
From the radiological point of view, resolution of lung
collapse had occurred in 60% of patients after 2 weeks, with
resolution of lobe atelectasis in 76% (n= 29) of patients after
6 weeks.
Our results were in accordance with, Gerard J. et al. [18],
who described in this case series, cryotherapy provides a
non-operative mechanism of improving airway patency and
may be used in combination with other treatment modalities
to provide optimal end-of-life care to patients who otherwise
may not have been offered any intervention.
Maiwand et al. [5], who reported that a total of 521 patients
with advanced obstructive tracheobronchial malignancy
underwent cryosurgery. The tumor was shrunk or eradicated
and lung atelectasis was improved. Hemoptysis, cough,
dyspnea and chest pain were improved. Median survival was
8.2 months and 1- and 2-year survival was 38.4% and
15.9%, respectively.
Yu et al. [19], who investigated the effect of endobronchial
cryosurgery in 92 patients with central bronchial carcinoma
using CO2 as the cryogen. Tumor complete remission (CR)
was achieved in 51 (55.4%) patients and partial remission
(PR) in 31 (37.7%) patients. Cough, hemoptysis, dyspnea,
and chest pain were improved in 73.9%, 98.0%, 75.0%, and
50.0% of the patients.
In other studies, a symptomatic improvement has been
reported with complete or partial restoration of airway
potency in over 90% of patients using cryotherapy, a signifi-
cant goal of therapy in the palliative management of these
patients [20,21].
Limitations of this study, were small number of the study
population, and results were not correlated with age, disease
stage, and tumor cell type.
In conclusion, in our case series, we reported the successful
use with high safety profile of cryotherapy with flexible
bronchoscopy to treat central airway obstruction due to endo-
bronchial malignant lesions. The key efficacy outcomes are
improved respiratory function and quality of life.
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